Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

July 31, 2015 8:07 AM ET


Company Overview of Eagle Pharmaceuticals Inc.

Company Overview

Eagle Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers argatroban to treat heparin-induced thrombocytopenia; and Ryanodex injectable suspension for the treatment of malignant hyperthermia. It develops EP-3101, a bendamustine ready to dilute (RTD) liquid and EP-3102, a bendamustine short infusion time RTD liquid for the treatment of chronic lymphocytic leukemia and indolent non-Hodgkin's lymphoma;; and EP-4104, a dantrolene for the treatment of exertional heat stroke. The company also develops EP-5101 (pemetrexed) as RTD liquid, whi...

50 Tice Boulevard

Suite 315

Woodcliff Lake, NJ 07677

United States

Founded in 2007

30 Employees



Key Executives for Eagle Pharmaceuticals Inc.

Chief Executive Officer, President and Director
Age: 55
Total Annual Compensation: $449.6K
Chief Financial Officer
Age: 62
Total Annual Compensation: $265.9K
Chief Medical Officer and Head of Research & Development
Age: 56
Total Annual Compensation: $303.8K
Chief Scientific Officer
Age: 56
Total Annual Compensation: $352.4K
Compensation as of Fiscal Year 2014.

Eagle Pharmaceuticals Inc. Key Developments

Eagle Pharmaceuticals’ RTU Bivalirudin NDA Accepted for Filing

Eagle Pharmaceuticals Inc. announced that the 505 (b)(2) New Drug Application (NDA) for its novel ready-to-use bivalirudin product has been accepted for filing by the U.S. Food and Drug Administration (FDA). This 505(b)(2) NDA requests FDA approval of Eagle’s RTU bivalirudin product for the treatment of patients: undergoing percutaneous coronary intervention (PCI) with use of glycoprotein IIb/IIIa inhibitor, undergoing PCI with, or at risk of, heparin-induced thrombocytopenia and thrombosis syndrome, or with unstable angina undergoing percutaneous transluminal coronary angioplasty (PTCA). Eagle’s RTU bivalirudin product, which contains the same active ingredient as Angiomax, is administered as an IV solution at the same dose and rate. Eagle’s liquid formulation will allow for immediate administration, with no reconstitution nor initial dilution required, reducing work flow and the risk of dosing errors. Eagle’s intellectual property pertaining to RTU bivalirudin includes two issued patents and an additional patent pending at the U.S. Patent and Trademark Office.

Eagle Pharmaceuticals Inc.(NasdaqGM:EGRX) added to Russell 2000 Index

Eagle Pharmaceuticals Inc. will be added to Russell 2000 Index

Eagle Pharmaceuticals Inc.(NasdaqGM:EGRX) added to Russell 3000 Index

Eagle Pharmaceuticals Inc. will be added to the Russell 3000 Index.

Similar Private Companies By Industry

Company Name Region
Artecel Sciences United States
Cyagra Inc United States
Nomocan Pharmaceuticals LLC United States
Care Connectors, Inc. United States
Akron Biotechnology, LLC United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Eagle Pharmaceuticals Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at